Response
We appreciate the letter by Dr Kessler, who highlights critical issues in the development and use of composite endpoints. From our perspective, 1 a treatment is of interest if it prolongs or enhances quality of life, prevents events, or saves money without sacrificing longevity or quality of life. Thus, when measuring treatment effects, it is critical to measure the likelihood over time of remaining alive and free of events. Composite endpoints can assist in this effort in 2 ways.
Composite endpoints translate into higher overall event rates compared with any component alone, resulting in smaller cohorts needed to achieve desired power to detect specified treatment effects. Thus, important questions may be answered more quickly. In developing composite endpoints, the treatment is assumed to affect each component comparably, although perhaps not equally. If a treatment has no effect on a component, the result would be to dilute treatment effects on the composite and thus reduce the power of comparisons. As Dr Kessler suggests, if the components of a composite are quite diverse and of widely different importance, the composite may not be a very sensible or useful endpoint. This is especially true when the components become softer or more difficult to define or adjudicate. Regardless of the components included, a reasonable secondary analysis would examine qualitatively the treatment effect on each component.
Although a treatment may reduce the risk of nonfatal events, such treatment comparisons become problematic when many deaths also occur. Patients who die without having the nonfatal event cannot be counted in the event-free group or in the group with the event, because they might have had the event had they lived longer. Thus, composite endpoints must include mortality to capture the overall effects of treatment. The statistical theory behind this approach is contained in literature on competing risk analysis.
For treatments unlikely to have statistically or clinically important effects on mortality, we continue to urge measurement of event-free survival, including the least severe event likely to be affected by treatment and more severe events. Regarding the weighting of death relative to other events, many patients consider disabling stroke to be as severe as or worse than death. 2 Although we 3 and others 4 have described weighted composite endpoints, major disagreements about appropriate weighting have prevented adoption of this approach. Much more research is needed into composite endpoints, especially regarding the perspective of the patients affected by the resulting therapeutic choices.
